Avecho Biotechnology Limited (F:OEZ) — Market Cap & Net Worth
Market Cap & Net Worth: Avecho Biotechnology Limited (OEZ)
Avecho Biotechnology Limited (F:OEZ) has a market capitalization of $25.76 Million (€22.04 Million) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #24234 globally and #2098 in its home market, demonstrating a 16.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avecho Biotechnology Limited's stock price €0.01 by its total outstanding shares 3680464396 (3.68 Billion). See Avecho Biotechnology Limited capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Avecho Biotechnology Limited Market Cap History: 2015 to 2026
Avecho Biotechnology Limited's market capitalization history from 2015 to 2026. Data shows growth from $12.91 Million to $30.12 Million (0.00% CAGR).
Avecho Biotechnology Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avecho Biotechnology Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.28x
Avecho Biotechnology Limited's market cap is 17.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $73.15 Million | $1.59 Million | -$17.31 Million | 46.06x | N/A |
| 2017 | $38.73 Million | $1.15 Million | -$8.55 Million | 33.66x | N/A |
| 2018 | $4.30 Million | $1.25 Million | -$3.99 Million | 3.44x | N/A |
| 2019 | $2.15 Million | $4.24 Million | $849.96K | 0.51x | 2.53x |
| 2020 | $62.39 Million | $384.63K | -$2.63 Million | 162.21x | N/A |
| 2021 | $30.12 Million | $1.06 Million | -$5.15 Million | 28.43x | N/A |
| 2022 | $27.97 Million | $1.21 Million | -$2.34 Million | 23.19x | N/A |
| 2023 | $4.30 Million | $473.55K | -$3.44 Million | 9.09x | N/A |
| 2024 | $4.30 Million | $1.13 Million | -$3.12 Million | 3.80x | N/A |
| 2025 | $21.51 Million | $1.25 Million | -$4.42 Million | 17.28x | N/A |
Competitor Companies of OEZ by Market Capitalization
Companies near Avecho Biotechnology Limited in the global market cap rankings as of August 4, 2026.
Key companies related to Avecho Biotechnology Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Avecho Biotechnology Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Avecho Biotechnology Limited's market cap moved from $12.91 Million to $ 30.12 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €30.12 Million | +40.00% |
| 2025 | €21.51 Million | +400.00% |
| 2024 | €4.30 Million | 0.00% |
| 2023 | €4.30 Million | -84.62% |
| 2022 | €27.97 Million | -7.14% |
| 2021 | €30.12 Million | -51.72% |
| 2020 | €62.39 Million | +2800.00% |
| 2019 | €2.15 Million | -50.00% |
| 2018 | €4.30 Million | -88.89% |
| 2017 | €38.73 Million | -47.06% |
| 2016 | €73.15 Million | +466.67% |
| 2015 | €12.91 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Avecho Biotechnology Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.76 Million USD |
| MoneyControl | $25.76 Million USD |
| MarketWatch | $25.76 Million USD |
| marketcap.company | $25.76 Million USD |
| Reuters | $25.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more